• Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression 

  Lheureux, Stephanie; Prokopec, Stephenie; Oldfield, Leslie E.; Gonzalez-Ochoa, Eduardo; Bruce, Jeff; Wong, Derek; OAKNIN, ANA (American Association for Cancer Research, 2023-09-15)

• Transfusion-transmission of hepatitis E virus through red blood cell transfusion but not through platelet concentrates: A case report from Spain 

  Ojea, Ana María; Seco, Carolina; Mata, Pablo; Muñoz, María del Carmen; Álvarez Argüelles, Marta Elena; RODRIGUEZ-FRIAS, FRANCISCO; QUER, JOSEP; Rando Segura, Ariadna (Wiley, 2023-09)

• Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry 

  Garre, Ana; Iborra, Marisa; Sierra-Ausín, Mónica; Barreiro de Acosta, Manuel; Fernández Clotet, Agnès; Monfort Miquel, David; PIQUERAS CANO, MARTA; Chaparro, María (Oxford University Press, 2021-11-08)

• COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 

  Chatzikonstantinou, Thomas ; Kapetanakis, Anargyros; Scarfo', Lydia; Allsup, David; Cabrero, Alejandro Alonso; Cuéllar-García, C.; KARAKATSOULIS, GEORGIOS (Springer Nature, 2021-12)

• The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program 

  Levink, Iris; Jaarsma, Sanne C.; Koopmann, Brechtje D. M.; van Riet, Priscilla; Overbeek, Kasper; Meziani, Jihane; Pando, Elizabeth (Wiley, 2023-09)

View more